TY - JOUR
T1 - EPOS2020: a major step forward
AU - Fokkens, W. J.
PY - 2020
Y1 - 2020
N2 - Together with this issue of Rhinology the new European Position Paper on Rhinosinusitis and Nasal Polyps will see the light. The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 like paediatric CRS, sinus surgery, exacerbations of CRS and the prevention of CRS. EPOS2020 also involved new stakeholders, like neurologists, immunologists, pharmacists and patients and address new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestion for future research in this area and offer updated guidance for definitions and outcome measurements in research in different settings.
AB - Together with this issue of Rhinology the new European Position Paper on Rhinosinusitis and Nasal Polyps will see the light. The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 like paediatric CRS, sinus surgery, exacerbations of CRS and the prevention of CRS. EPOS2020 also involved new stakeholders, like neurologists, immunologists, pharmacists and patients and address new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestion for future research in this area and offer updated guidance for definitions and outcome measurements in research in different settings.
UR - http://www.scopus.com/inward/record.url?scp=85079778288&partnerID=8YFLogxK
U2 - https://doi.org/10.4193/Rhin20.401
DO - https://doi.org/10.4193/Rhin20.401
M3 - Editorial
C2 - 32078669
SN - 0300-0729
VL - 58
SP - 1
JO - Rhinology
JF - Rhinology
IS - 1
ER -